On October 31, 2023, the opening ceremony of the "National Human Brain Health Project" joint laboratory was initiated by Beijing Hotgen Biotech Co., LTD. ( "Hotgen Biotech"), Shenzhen Zhiyuan Biomedical Co., LTD. ( "Zhiyuan Biomedical ") and Beijing Sungen Biomedical Technology Co., LTD. ( "Sungen Biomedical"). Mr. Lin Changqing, Chairman and President of Hotgen Biotech, Professor Liu Ruitian, Chief scientist of Zhiyuan Biomedical, and Professor Sun Zhiwei, General manager of Sungen Biomedical, jointly inaugurated the official operation of the "National Human Brain Health Project" joint laboratory.
Fig. The official opening ceremony of the "National Human Brain Health Project" Joint laboratory
Brain is the most important human organ. "Brain research program" have been announced in the United States, European Union, Japan and other countries. After years of planning, China's "brain science and brain research" after being included in the "13th Five-Year Plan", was again listed as the national "14th Five-Year Plan", becoming one of the seven "science and technology frontier research" projects.
Neurologic and psychiatric diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), autism, and depression urgently need advances in brain science to provide solutions. According to the statistics of the World Health Organization, brain diseases account for 28% in terms of social burden, more than cancer and cardiovascular diseases. Alzheimer's disease currently affects 50 million people worldwide. With the increase of human life expectancy, the prevalence of Alzheimer's disease is rising. It is expected that by 2050, the number of patients with Alzheimer's disease will increase to more than 150 million. China has about 10 million Alzheimer's patients, ranking first in the world, and is expected to exceed 40 million by 2050.
Mr. Lin Changqing, Chairman and president of Beijing Hotgen Biotech Co., Ltd., said at the ceremony: Hotgen Biotech is a high-tech enterprise with the mission of "developing biotechnology for the benefit of human health". We always focus on scientific and technological innovation, constantly increase R&D investment, actively develop new products, and continue to explore new diagnostic technologies and diagnostic markers. At the same time, we explore new business areas, and gradually increase investment in antibody drugs, nucleic acid drugs, live bacteria drugs and other therapeutic fields, to achieve the company's two goals of in vitro diagnosis and biopharmaceuticals.
"National Human Brain Health Project" is one of the "three major Chinese health projects" created by Hotgen Biotech (Chinese liver health project, National Human Brain Health project, Chinese cancer early diagnosis and early screening project), and has been developed for many years in the diagnosis of brain health-related diseases, including Alzheimer's disease, Parkinson's disease and so on. Hotgen Biotech has cooperated with the National Clinical Medical Research Center for Neurological Diseases and the Chinese Stroke Society to jointly build an innovative research platform - "Tiantan-Hotgen Brain Science Research Center". The establishment of the "National Brain Health Project" joint laboratory with Sungen Biomedical and Zhiyuan Biomedical, is another important milestone in the diagnosis and treatment of brain health-related diseases.
Professor Liu Ruitian, chief scientist of Shenzhen Zhiyuan Biomedical Co., Ltd. said that, Zhiyuan Biomedical is committed to solving the basic and frontier problems of neurodegenerative diseases, and promoting the upgrade of antibody drug research and development. The company is currently conducting research of original therapeutic antibodies and diagnostic kits for Alzheimer's disease, Parkinson's disease, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and other diseases. Among them, the self-developed anti-Aβ specific antibody can inhibit Aβ aggregates and effectively improve cognitive impairment and pathological changes in AD. The results of preclinical studies show that this antibody has more advantages than peer candidates. Zhiyuan Biomedical has started the construction of "AI drug simulation calculation and analysis platform", "antibody drug design, research and development platform", "antibody drug PK, pharmacology, efficacy evaluation platform", and "disease diagnosis and development platform", actively promoting the research and development of original biological drugs, to become the world's leading R&D center for treatment of neurodegenerative diseases.
Professor Sun Zhiwei, General manager of Beijing Sungen Biomedical Technology Co., LTD., said at the ceremony, Sungen Biomedical is a bio-high-tech enterprise focusing on R&D and industrialization of innovative antibody drugs for cardiovascular and cerebrovascular diseases. Since its establishment 5 years ago, the company has adhered to independent innovation and established molecular discovery platforms such as "large-capacity fully synthetic antibody library molecular discovery platform", "hybridoma antibody molecular discovery platform", "single B cell sorting antibody molecular discovery platform" and "AI-assisted antibody discovery platform with advanced technology" for cardiovascular and cerebrovascular related diseases. It has improved core technology platforms such as pilot R & D and production platform, quality control platform, and industrialization platform. Sungen Biomedical has a number of FIC antibodies about to enter the IND stage.
The operation of the "National Human Brain Health Project" joint laboratory will speed up R & D of antibody drugs for cardiovascular and cerebrovascular diseases.
The operation of the "National Human Brain Health Project" joint laboratory fully integrates the advantages of three companies, with synergistic advantages and resource sharing. It will promote the research and development of brain science to a new level. In the upcoming days, the joint laboratory will achieve more remarkable results in human health.
Updated: Aug 19, 2024
